8月26日,礼来公司公布了其在研口服GLP-1受体激动剂orforglipron的III期临床试验ATTAIN-2的积极顶线结果。这项针对合并2型糖尿病的肥胖或超重成人患者的研究表明,orforglipron所有三个剂量组均达到了主要终点和所有关键次要终点。一、疗效数据:减重与降糖双达标研究结果显示,在接受最高剂量36mg治疗的患者中,72周时平均体重下降达10.5%(10.4公斤),显著优于...
Source Link8月26日,礼来公司公布了其在研口服GLP-1受体激动剂orforglipron的III期临床试验ATTAIN-2的积极顶线结果。这项针对合并2型糖尿病的肥胖或超重成人患者的研究表明,orforglipron所有三个剂量组均达到了主要终点和所有关键次要终点。一、疗效数据:减重与降糖双达标研究结果显示,在接受最高剂量36mg治疗的患者中,72周时平均体重下降达10.5%(10.4公斤),显著优于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.